[go: up one dir, main page]

WO1996003993A3 - Modulation de l'activite fonctionnelle de thymocytes et de lymphocytes t - Google Patents

Modulation de l'activite fonctionnelle de thymocytes et de lymphocytes t Download PDF

Info

Publication number
WO1996003993A3
WO1996003993A3 PCT/US1995/009915 US9509915W WO9603993A3 WO 1996003993 A3 WO1996003993 A3 WO 1996003993A3 US 9509915 W US9509915 W US 9509915W WO 9603993 A3 WO9603993 A3 WO 9603993A3
Authority
WO
WIPO (PCT)
Prior art keywords
cgrp
administering
amount
modulation
inhibitor
Prior art date
Application number
PCT/US1995/009915
Other languages
English (en)
Other versions
WO1996003993A2 (fr
Inventor
Karen Bulloch
Bruce S Mcewen
Original Assignee
Univ Rockefeller
Karen Bulloch
Bruce S Mcewen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller, Karen Bulloch, Bruce S Mcewen filed Critical Univ Rockefeller
Publication of WO1996003993A2 publication Critical patent/WO1996003993A2/fr
Publication of WO1996003993A3 publication Critical patent/WO1996003993A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne la modulation des réponses immunitaires de cellules et la modulation ou l'inhibition de cancers des thymocytes ou thymomes. Selon un premier aspect, le présente invention concerne un procédé pour supprimer une réponse immune en administrant de la déshydroépiandrostérone (DHEA). Selon un autre aspect, l'invention concerne un procédé pour augmenter une réponse immune, consistant à administrer une certaine quantité d'un inhibiteur du peptide apparenté au gène de la calcitonine (CGRP) comme, par exemple l'antagoniste du CGRP qu'est CGRP8-37 ou une certaine quantité d'un inhibiteur de la DHEA. L'invention concerne également un procédé pour traiter un cancer du thymus ou thymone consistant à administrer une quantité de CGRP suffisante pour induire une apoptose des cellules du cancer du thymus ou thymome. L'invention concerne en outre un procédé pour empêcher des atteintes aux tissus, consistant à administrer une quantité d'inhibiteur du CGRP suffisante pour inhiber l'apoptose de cellules dans la région de l'atteinte aux tissus. L'invention concerne encore un procédé pour identifier un agent capable d'inhiber l'apoptose due au CGRP.
PCT/US1995/009915 1994-08-05 1995-08-07 Modulation de l'activite fonctionnelle de thymocytes et de lymphocytes t WO1996003993A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28686494A 1994-08-05 1994-08-05
US08/286,864 1994-08-05

Publications (2)

Publication Number Publication Date
WO1996003993A2 WO1996003993A2 (fr) 1996-02-15
WO1996003993A3 true WO1996003993A3 (fr) 1996-06-20

Family

ID=23100503

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/009915 WO1996003993A2 (fr) 1994-08-05 1995-08-07 Modulation de l'activite fonctionnelle de thymocytes et de lymphocytes t

Country Status (1)

Country Link
WO (1) WO1996003993A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
CN1055640C (zh) * 1996-11-29 2000-08-23 沃维汉 人降钙素基因相关肽脂质体组合物及其制法
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
JP2021501784A (ja) * 2017-11-06 2021-01-21 オークランド ユニサービシーズ リミティド ペプチド複合体ｃｇｒｐ受容体アンタゴニストおよびその調製方法および使用方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
US4628052A (en) * 1985-05-28 1986-12-09 Peat Raymond F Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
EP0408294A2 (fr) * 1989-07-10 1991-01-16 Amylin Pharmaceuticals, Inc. Utilisation d'un antagonist de amyline pour l'obtention d'un médicament destiné au traitement de l'obésitÀ© et de l'hypertonie, et des troubles connexes
WO1993021771A1 (fr) * 1992-05-01 1993-11-11 University Of Utah Compositions et procedes visant a reguler la production d'interleukine-6 in vivo
WO1993021911A1 (fr) * 1992-05-06 1993-11-11 Kabi Pharmacia Ab Procede et moyen pour prevenir la contraction de la pupille dans l'×il
WO1994008589A1 (fr) * 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Traitement du lupus erythemateux systemique a la deshydroepiandrosterone

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
US4628052A (en) * 1985-05-28 1986-12-09 Peat Raymond F Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
EP0408294A2 (fr) * 1989-07-10 1991-01-16 Amylin Pharmaceuticals, Inc. Utilisation d'un antagonist de amyline pour l'obtention d'un médicament destiné au traitement de l'obésitÀ© et de l'hypertonie, et des troubles connexes
WO1993021771A1 (fr) * 1992-05-01 1993-11-11 University Of Utah Compositions et procedes visant a reguler la production d'interleukine-6 in vivo
WO1993021911A1 (fr) * 1992-05-06 1993-11-11 Kabi Pharmacia Ab Procede et moyen pour prevenir la contraction de la pupille dans l'×il
WO1994008589A1 (fr) * 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Traitement du lupus erythemateux systemique a la deshydroepiandrosterone

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COLEMAN, D.L. ET AL: "Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice", DIABETOLOGICA, vol. 23, no. 1, pages 830 - 833 *
DAYNES, R.A. ET AL: "Regulation of murine lymphokine production in vitro", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 171, no. 4, pages 979 - 996 *
LUCAS J.A. ET AL: "Prevention of autoantibody formation and prolonged survival in New Zealand Black/New Zealand White Fsub 1 mice fed dehydroisoandrosterone", J. CLIN. INVEST., 1985, 75/6 (2091-2093), USA *
MATSUNAGA A ET AL: "Dehydroisoandrosterone prevention of autoimmune disease in NZB/W F1 mice: lack of an effect on associated immunological abnormalities.", BIOCHIM BIOPHYS ACTA, SEP 15 1989, 992 (3) P265-71, NETHERLANDS *
SUZUKI, T. ET AL: "Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human Tcells", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 61, no. 2, pages 202-211 *
TANNEN, R.H. ET AL: "Reduced weight gain and delay of Coomb's positive hemolytic anemia in NZB mice treated with dehydroepiandrosterone (DHEA)", FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, vol. 41, pages 463A *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates

Also Published As

Publication number Publication date
WO1996003993A2 (fr) 1996-02-15

Similar Documents

Publication Publication Date Title
Fabunmi et al. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1,-2, and-3 in rabbit aortic smooth muscle cells
Kayahara et al. Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasion
Reich et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells
WO1999046279A3 (fr) INHIBITEURS DE LA 17β-HYDROXYSTEROIDE DESHYDROGENASE DU TYPE 5 ET DU TYPE 3 ET METHODES D'UTILISATION ASSOCIEES
MY114347A (en) Synergistic therapeutic compositions and methods.
ZA987491B (en) Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
CA2241981A1 (fr) Procede d'inhibition du photoviellissement de la peau
EP1748046A3 (fr) Inhibiteurs d'histone déacetylase
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
IL162836A (en) Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments and pharmaceutical compositions thereof
MY106484A (en) Combination therapy for phophylaxis and/or treatment of benign prostatic hyperplasia.
WO2003089457A3 (fr) Inhibiteurs peptidiques de la proteine kinase c$g(g) pour la gestion de la douleur
WO1993021942A3 (fr) Utilisation d'inhibiteurs de metalloprotease matricielle (mmp)
WO2001000198A3 (fr) Compositions et procede de traitement du cancer avec des compositions contenant un inhibiteur de l'activite du recepteur de l'endotheline
YU3902A (sh) Imidazoimidazoli i triazoli kao anti-inflamatorna sredstva
WO2001070675A3 (fr) Inhibiteurs d'histone desacetylase
WO2000021559A3 (fr) Facteur de blocage b destine a traiter une maladie d'origine immunitaire induite par complement
PL340561A1 (en) Application of a combination of a converting enzyme inhibitor and a diuretic in treating microcirculatory disorders
WO1996003993A3 (fr) Modulation de l'activite fonctionnelle de thymocytes et de lymphocytes t
DE69333639D1 (en) Trypsininhibitoren
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
TR199802638T2 (xx) Kanser tedavisinde naaladase inhibit�rleri kullan�m�.
ATE374618T1 (de) Verwendung von rekombinanten menschlichen uteroglobin zur behandlung von fibrotischen krankheitszuständen
MXPA03004209A (es) Composicion farmaceutica o cosmetica y uso de un inhbidor de proteina cinasa c con un inhibidor de metaloproteasas de la matriz para inhibir la migracion de celulas de langerhans.
AU8742198A (en) Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: CA,JP,US, EUROPEAN PATENT(AT,BE,DE,DK,FR,GB,IE,IT,LU,MC,NL,PT,SE)

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase